[BCRX] BioCryst Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 6.99 Change: 0.59 (9.22%)
Ext. hours: Change: 0 (0%)

chart BCRX

Refresh chart

Strongest Trends Summary For BCRX

BCRX is in the medium-term down -38% below S&P in 8 months and down -33% in 1 year and down -81% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop drugs through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as to treat acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company?s product candidates also comprise BCX4161, a Phase II oral serine protease inhibitor for hereditary angioedema (HAE); and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filovi

Fundamental Ratios
Shares Outstanding EPS-0.63 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 365.62% Sales Growth - Q/Q25.34% P/E-8.81
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-38.67% ROE-78.01% ROI
Current Ratio1.32 Quick Ratio Long Term Debt/Equity Debt Ratio0.96
Gross Margin Operating Margin-311.12% Net Profit Margin-295.81% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.5 M Cash From Investing Activities-3.95 M Cash From Operating Activities-3.73 M Gross Profit6.81 M
Net Profit-15.16 M Operating Profit-14.43 M Total Assets129.87 M Total Current Assets81.37 M
Total Current Liabilities61.86 M Total Debt30 M Total Liabilities65.5 M Total Revenue6.83 M
Technical Data
High 52 week9.72 Low 52 week1.59 Last close2.11 Last change4.2%
RSI53.77 Average true range0.2 Beta1.24 Volume682.49 K
Simple moving average 20 days4.52% Simple moving average 50 days-13.79% Simple moving average 200 days-56.16%
Performance Data
Performance Week31.88% Performance Month-11.34% Performance Quart-17.9% Performance Half-40.4%
Performance Year-74.3% Performance Year-to-date-73.85% Volatility daily6.41% Volatility weekly14.33%
Volatility monthly29.38% Volatility yearly101.76% Relative Volume907.2% Average Volume2.07 M
New High New Low


2020-05-27 23:35:10 | BioCryst Prices Public Offering of Common Stock and Pre-Funded Warrants

2020-05-27 18:21:50 | BioCryst Plans to Raise $100 Million

2020-05-27 16:01:10 | BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants

2020-05-26 07:00:10 | BioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress

2020-05-19 15:18:55 | Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'

2020-05-18 14:47:12 | Moderna COVID-19 vaccine data is ‘baby-step’ in right direction: Expert

2020-05-18 09:30:01 | Moving Average Crossover Alert: BioCryst Pharmaceuticals

2020-05-18 09:21:01 | Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals BCRX Stock?

2020-05-15 07:53:11 | BioCryst's Shares March Higher, Can It Continue?

2020-05-15 07:00:10 | BioCryst Celebrates HAE Patients with HAE Global Walk

2020-05-13 11:30:03 | Is BioCryst Pharmaceuticals BCRX Stock Outpacing Its Medical Peers This Year?

2020-05-11 14:45:00 | Here's Why Shares of BioCryst Pharmaceuticals Jumped Higher Today

2020-05-11 14:45:00 | Here's Why Shares of BioCryst Pharmaceuticals Jumped Higher Today

2020-05-07 13:07:41 | Industry Analysts Just Made A Meaningful Upgrade To Their BioCryst Pharmaceuticals, Inc. NASDAQ:BCRX Revenue Forecasts

2020-05-07 07:00:10 | BioCryst to Present at Upcoming Investor Conferences

2020-05-07 01:37:56 | Edited Transcript of BCRX earnings conference call or presentation 6-May-20 12:30pm GMT

2020-05-06 19:31:11 | Biocryst Pharmaceuticals Inc BCRX Q1 2020 Earnings Call Transcript

2020-05-06 08:55:12 | BioCryst Pharmaceuticals BCRX Reports Q1 Loss, Tops Revenue Estimates

2020-05-06 07:42:45 | Recap: BioCryst Pharmaceuticals Q1 Earnings

2020-05-06 07:00:10 | BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones

2020-05-05 07:00:10 | New Composition of Matter Patent Allowance Extends Protection for Berotralstat in U.S. Market by Four Years to 2039

2020-05-04 16:15:10 | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-04-29 13:17:05 | BioCryst BCRX to Report Q1 Earnings: What's in the Cards?

2020-04-29 13:06:00 | BioCryst Pharma Tests Drug Similar to Gilead's Remdesivir

2020-04-29 12:34:04 | Will BioCryst Pharmaceuticals BCRX Report Negative Earnings Next Week? What You Should Know

2020-04-27 17:50:09 | BioCryst Pharmaceuticals BCRX Stock Sinks As Market Gains: What You Should Know

2020-04-27 11:30:03 | Is BioCryst Pharmaceuticals BCRX Outperforming Other Medical Stocks This Year?

2020-04-26 07:51:40 | 3 Biotech Stocks Under $4 With Big Upside Potential

2020-04-22 07:00:10 | BioCryst to Report First Quarter 2020 Financial Results on May 6

2020-04-22 06:16:05 | How Does BioCryst Pharmaceuticals, Inc. NASDAQ:BCRX Affect Your Portfolio Volatility?

2020-04-21 12:19:04 | RedHill's Oncology Candidate to be Tested for Coronavirus

2020-04-20 09:06:01 | Top Ranked Momentum Stocks to Buy for April 20th

2020-04-15 09:36:01 | Are Options Traders Betting on a Big Move in BioCryst Pharmaceuticals BCRX Stock?

2020-04-14 18:29:06 | BioCryst Latest to Enter Covid-19 Battle

2020-04-14 14:32:40 | Birmingham work will support new clinical trial for COVID-19 treatment

2020-04-13 12:27:04 | BioCryst Begins Study on Galidesivir for Coronavirus Infection

2020-04-13 09:54:12 | Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics

2020-04-10 14:06:23 | RTP drugmaker will test Ebola treatment on COVID-19 patients

2020-04-09 17:52:00 | BioCryst stock rallies on start of coronavirus drug study

2020-04-09 16:45:10 | BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19

2020-04-08 07:00:10 | BioCryst to Present at 19th Annual Needham Healthcare Conference

2020-04-03 07:07:11 | BioCryst Sees Hammer Chart Pattern: Time to Buy?

2020-04-03 07:00:10 | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-04-02 12:28:04 | The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore

2020-04-02 07:00:10 | BioCryst Appoints Anthony Doyle Chief Financial Officer

2020-04-01 08:18:12 | After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys

2020-03-30 07:00:10 | European Medicines Agency Validates Marketing Authorization Application for Oral, Once-Daily Berotralstat BCX7353 to Prevent HAE Attacks

2020-03-24 17:31:08 | Edited Transcript of BCRX earnings conference call or presentation 5-Mar-20 1:30pm GMT

2020-03-17 06:41:25 | Here's Why BioCryst Pharmaceuticals NASDAQ:BCRX Can Manage Its Debt Despite Losing Money